We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





New Purpose-Built COVID-19 LIMS Solution Jump-Starts COVID-19 Testing and Research

By LabMedica International staff writers
Posted on 11 May 2020
Print article
Illustration
Illustration
A new purpose-built COVID-19 laboratory information management system (LIMS) solution can jump-start the ability of laboratories everywhere to enter biospecimens into a biobank and rapidly begin conducting COVID-19-related testing and research.

The new COVID-19 Biobanking Accelerator is built on the LabVantage Solutions, Inc.’s (Somerset, NJ, USA) industry-leading LIMS and Biobanking platforms used by clinical laboratories around the globe. Delivered as a comprehensive Software-As-A-Service (SaaS) solution, the LabVantage COVID-19 Biobanking Accelerator requires no infrastructure investment. Being pre-configured means minimal implementation time is needed with a go-live start possible in less than four weeks.

The LIMS Accelerator includes full biobanking capabilities and COVID-19 extraction and testing workflows with related master data for rapid use. It incorporates multiple protocols defined by the CDC for COVID-19 testing, and it can easily accommodate the addition of standard and customer-determined protocols for testing using a variety of approaches, such as RT-PCR, isothermal nucleic acid amplification and serology.

“Widespread laboratory testing is a critical component in the battle to control the coronavirus pandemic sweeping the globe. At LabVantage, we mobilized our decades of expertise to rapidly deliver a new purpose-built Biobanking LIMS to support COVID-19 testing and research,” said LabVantage CEO John Heiser. “It incorporates our deep knowledge of biobanking along with numerous features designed to make it easy for laboratories to acquire, implement and use the most powerful LIMS on the market for their COVID-19 testing. The LIMS Accelerator is also scalable, an important attribute as testing volumes escalate. Our outstanding service team stands ready to help customers begin using the package almost immediately. We are honored to have the opportunity to contribute to the laboratory testing and research that is critical to controlling and ultimately eliminating this devastating pandemic.”

Related Links:
LabVantage Solutions, Inc.

Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Auto-Chemistry Analyzer
CS-1200
New
PSA Test
Human Semen Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.